References
- Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts. 2026. At: www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/summary
- Schutte AE, Bennett B, Chow CK, et al. National Hypertension Taskforce of Australia: a roadmap to achieve 70% blood pressure control in Australia by 2030. Med J Aust. 2024;221(3):126-134.
- Queensland Government. Queensland Community Pharmacy Chronic Conditions Management Pilot Cardiovascular Disease (CVD) Risk Reduction Program – hypertension. Clinical protocol. At: www.health.qld.gov.au/__data/assets/pdf_file/0015/1451103/cvd-hypertension-protocol.pdf
- Xu X, Land MA, James S, et al. Potassium-enriched salt for patients with hypertension: a Hypertension Australia and National Hypertension Taskforce of Australia Position Statement. J Hypertens. 2026;44(1):1-5.
- Heart Foundation of Australia. Obesity and cardiovascular disease. 2026. At: www.heartfoundation.org.au/for-professionals/obesity-cvd-consensus-statement
- MacIntyre CR, Mahimbo A, Moa AM, et al. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016;102:1953–1956.
- Nguyen TQ, Zhao E, Weinman AL, et al. Respiratory viral contribution to acute myocardial infarction: a time series and spatiotemporal analysis in Victoria, Australia 2010–2022. medRxiv. 2026. doi:10.64898/2026.01.30.26345252.
- Pharmaceutical Benefits Scheme. PBS restriction changes for antihypertensive dual therapy fixed dose combinations. 2026. At: www.pbs.gov.au/reviews/pbs-restriction-changes-for-antihypertensive-dual-therapy-fixed-dose-combinationsi
- Raffoul N, Brims K, Knight J, et al. Targeted cardiovascular risk screening through an SMS programme (Text to Detect) in general practice: a three-arm, parallel group, randomised controlled trial. Lancet Prim Care. 2025;1(5):100043. At: www.thelancet.com/journals/lanprc/article/PIIS3050-5143(25)00043-3/fulltext
